The pan-PI3K inhibitor Buparlisib combined with paclitaxel demonstrated improved progression-free survival in the treatment of recurrent or metastatic HNSCC patients [14]. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.